Sudhir Borgonha, MD

Sudhir Borgonha, MD has a wealth of experience in the medical field. Sudhir began their career in 2006 as Medical Director at Translational Medicine Inc. In 2011, they moved to Ethypharm as Medical Director. In 2014, they joined Strand Life Sciences as Medical Director and was responsible for leading medical functions, clinical research programs, and translational medicine studies. In 2018, they took on the role of Director of Translational Medicine at the Fanconi Anemia Research Fund, where they were responsible for funding international university and industry partners in gene therapy, early cancer diagnostics and clinical management. In 2020, they were appointed Vice President of Clinical Development at Capricor Therapeutics, Inc., where they were responsible for leading overall clinical development of product pipeline, including ongoing trials in Covid and DMD, and advancing platform technology for delivery of gene products for multiple therapeutic indications. Most recently, in 2021, they were appointed Vice President of Clinical Development (Oncology) at Denovo Biopharma.

Sudhir Borgonha, MD obtained a Doctor of Medicine (MD) from St. John's Medical College in 1997 and a Master of Science (MS) in Business from the MIT Sloan School of Management in 2001.